New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
07:10 EDTNLNKNewLink Genetics weakness creates buying opportunity, says Cantor
Cantor reports that NewLink's stock has been pressured since the announcement of the continuation of the IMPRESS trial of its pancreatic cancer drug to the next review point. The firm expected this to occur but notes that the timing of the continuation has raised concerns about survival rates and the possibility that the control arm is performing better than expected. Cantor thinks it's too early to be concerned about these issues, and raised its price target on the shares to $34 from $30 while keeping a Buy rating on the stock.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
10:32 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
February 26, 2015
13:57 EDTNLNKNewLink Genetics volatility pulls back after Q4
Subscribe for More Information
10:36 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
February 25, 2015
10:37 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: FUEL GREK NLNK HLSS SLXP LL VNDA AWAY DWA TRUE
February 19, 2015
08:38 EDTNLNKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
February 18, 2015
10:42 EDTNLNKOptions with increasing implied volatility: NLNK TLM
Subscribe for More Information
10:39 EDTNLNKNewLink Genetics volatility elevated
NewLink Genetics February call option implied volatility of 159, March s at 149, April is at 135; compared to its 26-week average of 130 according to Track Data, suggesting large price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use